Cytogenetic lesions that are associated with impaired survival have been identified in myeloma, and there is an aim to use such lesions to define high risk disease in a risk-adapted therapeutic approach. The lesions generally accepted to constitute high risk lesions are t(4;14), t(14;16), t(14;20), del(17p) and +1q. We identified two regions of 1p that have prognostic impact when deleted: 1p32.3 and 1p12. Deletion of 1p32.3 targets CDKN2C, and it only impacts prognosis in patients treated with ASCT.
INTRODUCTION
High risk genetic lesions can be divided into primary genetic events, namely translocations involving the IGH gene at 14q32, and secondary genetic events which usually constitute chromosomal gains or deletions (1) . IGH translocations that have been associated with short survival in myeloma include t(4;14), t(14;16) and t (14;20) , whilst structural chromosomal abnormalities that have been shown to be important include deletion of 17p, involving the TP53 gene, and gain of 1q (2) (3) (4) (5) (6) (7) . A prognostic model incorporating these lesions with the International Staging System (ISS) has been described which identified patients with poor prognosis at diagnosis (8) .
Deletion of 1p has been identified as a common recurrent genetic event in myeloma that has prognostic significance when detected by conventional cytogenetics (9) (10) .
Several minimally altered regions on 1p have been identified, including 1p32.3, 1p31.3, 1p22.1-1p21.3 and 1p12 (11) . We have previously used an approach of focusing on regions with recurrent homozygous deletions, as these are usually small, pathogenically relevant, and allow for the definition of critically de-regulated genes (12) . We described recurrent homozygous deletions of 1p32.3 which incorporate two genes, CDKN2C and FAF1, with homozygous deletion being associated with abrogation of expression of both of these genes (13) (14) . We found deletion of 1p32.3 to be associated with impaired survival in 510 newly presenting patients treated intensively (14) . In another study, genome wide correlation of CGH-defined genomic lesions with survival identified 1p31-32 as the only factor independently associated with prognosis in 131 patients treated with high dose melphalan and autologous stem cell transplantation (ASCT) (15) . Two data sets have, therefore, found loss of 1p32 to be prognostically significant in patients treated with ASCT, although its significance outside of this clinical context is unknown. We have previously identified recurrent Author Manuscript Published OnlineFirst on October 12, 2011; DOI: 10.1158/1078-0432.CCR- homozygous deletions of FAM46C at 1p12, identifying it as a gene with potential pathogenic relevance (11) . The next generation sequencing of 38 myeloma tumours recently found FAM46C to be frequently mutated, highlighting the potential significance of this gene (16) . It is not known whether abnormalities of 1p12 / FAM46C impact prognosis. We have also previously identified a region from 1p22.1-21.3 as being a region of potential significance as, although it did not harbour homozygous mutations, it was the most frequently deleted region (11) . Two candidate genes with down-regulated expression within this region (MTF2 and TMED5) were identified.
In this study we conducted an analysis of the survival associations of genetic lesions of 1p32.3, 1p22.1 and 1p12 in patients treated intensively and non-intensively, with conventional and thalidomide-based chemotherapy regimens, and have integrated gene expression and mutational analysis to define de-regulated genes on 1p.
MATERIALS AND METHODS

Patients
The MRC Myeloma IX trial (ISRCTN68454111) enrolled 1960 patients with newly diagnosed multiple myeloma requiring treatment, and received ethical approval from the MRC Leukaemia Data Monitoring and Ethics Committee (MREC 02/8/95). The design and results of which have been reported elsewhere, but in summary treatment followed two pathways, an intensive or a non-intensive pathway, based on patient age and performance status (17) (18) followed by ASCT. After the autograft procedure there was a second randomization to maintenance thalidomide versus no ongoing therapy. In the non-intensive pathway patients were randomized to either MP (melphalan and prednisolone) or CTDa (attenuated cyclophosphamide, thalidomide and dexamethasone) to maximum response, followed by the same maintenance randomization. Irrespective of treatment pathway, all patients underwent a bisphosphonate randomization to receive zoledronic acid or clodronic acid. Median follow up was 3.7 years. An extended data set for 1p12 FISH testing included patients randomized in the Myeloma IX trial along with other diagnostic myeloma samples referred to the Wessex Regional Cytogenetic laboratory.
Genetic Test Data Sets
Bone marrow aspirate and peripheral blood samples were taken from patients after informed consent. Bone marrow was purified for plasma cells using CD138 magnetic microbead cell selection (Miltenyi Biotec 
Gene Mapping and Expression Analysis
CD138 selected cells were stored in RLT buffer (Qiagen) at -80 o C immediately after purification until extraction. DNA and RNA were extracted using commercial kits as previously described (19) . 100 ng of tumor RNA was amplified using the 2-cycle target labeling kit and hybridized to Human Genome U133 Plus 2.0 arrays (Affymetrix), washed and scanned following the manufacturer's protocol. 500 ng of tumor and 500 ng of germ line DNA were used for mapping purposes. DNA was digested, amplified, labeled and hybridized to GeneChip mapping 500K arrays (Affymetrix) as previously described (19) (20) . SNP genotypes were derived as previously described using Affymetrix GCOS and GTYPE software (19) . Regions of gain or loss of heterozygosity were identified using dChip 2006 (www.dchip.org), and expression data were normalized using dChip. Microarray data are accessible through Gene Expression Omnibus Series accession number GSE15695.
FISH
FISH was performed on CD138 selected bone marrow samples. FISH analysis of 1p32.3 used two bespoke probes (RP11-278J17 and RP11-116M11) grown and labeled in the laboratory, as previously described (13) . FISH for 1p12 utilized the RP11-418J17 probe. A mixture of commercially available and bespoke probes were used as previously described to detect the presence of an immunoglobulin heavy chain (IGH) translocation, the common IGH translocation partners (MMSET at 4p16, CCND3 at 6p21, CCND1 at 11q13, MAF at 16q23 and MAFB at 20q12), hyperdiploid status using the iFISH ploidy classification, deletion of 13q14, 16q23, 17p13, 22q11 and gain of 1q21 (21) (22) . 
Mutation Analysis
Genomic DNA underwent whole genome amplification using the REPLI-g commercial kit (Qiagen) following the manufacturer's protocol. High resolution melt (HRM)
analysis was used to screen tumor DNA samples for genetic variants of FAM46C, using the Type It HRM commercial kit (Qiagen) and the Rotorgene Q real-time cycler (Qiagen). Primers were designed to span segments of approximately 250 bases (supplementary data, Table 2 Data were analyzed using the Rotorgene Q series software version 1.7. Samples identified as variants by HRM underwent purification using the QIAquick PCR purification kit (Qiagen) and were directly sequenced with BigDye terminators v3.1 (Applied Biosytems) on a 3500 Genetic Analyzer (Applied Biosystems). Variants that were not labeled as SNPs on Ensembl had constitutional DNA sequenced using DNA extracted from peripheral blood samples.
Statistical Methods
Statistical analysis was performed using R and SPSS version 19.0 (SPSS Inc., Chicago, USA). Survival curves were plotted using the Kaplan-Meier method.
Differences between curves were tested for statistical significance using the log-rank Similarly, there were no significant differences comparing intensively and nonintensively treated patients with del(1)(p32.3) in ISS stratification, length of 1p deletion, rate of homozygous 1p32.3 deletion or rate of co-segregation of 1p12 deletion (supplementary data, Table 3 ). In a multivariate analysis including these genetic variables, del(1)(p32.3) was significantly associated with adverse OS in the intensive arm (HR1.68 (1.11 -2.56), p=0.015). Surprisingly, the association of del(1)(p32.3) with favorable survival in the patients treated non-intensively remained weakly significant in multivariate analysis (HR 0.63 (0.39 -1.00), p=0.050). These data suggest that the paradoxical survival effect in the two arms is not due to a confounding variable but is associated with the 1p32.3 deletion.
The major differences between the intensive and non-intensive arms were treatment and patient age. The intensive pathway incorporated treatment with ASCT, whereas the non-intensive pathway did not. Whether a patient entered the intensive or nonintensive pathway was decided by the treating physician based on patient suitability for ASCT, with no defined age limit. However, in practice, the majority of patients under the age of 70 were treated intensively, whilst the majority of patients over the age of 70 were treated non-intensively. This raised the question as to whether del(1)(p32.3) was associated with adverse prognosis in the context of ASCT or young age, and taking this question further we investigated age and ASCT as factors in subgroup analyses. We examined the impact of del(1)(p32.3) in patients that received autograft and in young patients treated in the non-intensive pathway.
Although there was an intention-to-treat with ASCT in the intensive pathway, only 346/503 (68.6%) analyzable patients in the intensive arm received ASCT. The analysis of the association of del (1) 
was not associated with OS in young patients that were not autografted suggests that this may be a treatment-specific effect.
To investigate the biological basis of this effect, the deletions were defined in more detail. Of the 114 patients with gene mapping data, 6 had a homozygous deletion of this region, with a further 12 having a hemizygous deletion. In our data set all the homozygous deletions affected two genes, CDKN2C and FAF1, and in order to try and define the key deleted gene we examined the mapping of an additional 565 In the majority of cases the deletions incorporated both CDKN2C and FAF1, but in 3
cases CDKN2C appeared to be the sole target of deletion.
The relationship of deletion and gene expression was examined. Although homozygous deletion of 1p32.3 abrogates expression of CDKN2C, hemizygous deletion was not associated with decreased expression. Moreover, although the homozygously deleted cases with abrogated CDKN2C expression were associated with short survival, low CDKN2C expression was not associated with impaired survival in other cases. In fact, the converse was true; patients with top quartile CDKN2C expression were associated with significantly shorter survival than those with bottom quartile expression (median OS 54.8 months low expression vs 36.1 months high expression, p=0.001). This is consistent with previously reported data linking high CDKN2C expression with a high proliferation rate (13, 23) . We have previously not found CDKN2C to be inactivated through mutation or methylation (13).
As hemizygous deletion was not associated with low expression, low expression was not associated with adverse survival, and other mechanisms of allelic inactivation have not been demonstrated, it is difficult to link the adverse survival associated with hemizygous deletion of 1p32.3 to modulation of CDKN2C. We examined FAF1, and found that hemizygous deletion of 1p32.3 was associated with decreased expression of this gene (218080_x_at fold change -1.48 (-1.29 to -1.73), P<0.001; 224217_s_at fold change -1.66 (-1.37 to -2.07), P<0.001). However, there was no association of low expression of these probes with short survival.
1p22.1
In a previous report we identified 1p22.1-21.3 as being the most frequently deleted of 1p, and the meta-analysis of the additional 565 publically available mapping cases confirmed this, with 22.5% of cases having a deletion of 1p22.1 (11) . We previously identified MTF2 and TMED5 as candidate genes within this region as both had significantly down-regulated expression in cases with deletion (11) . We now report that low expression of MTF2 was not associated with impaired OS or PFS. Moreover, no mutations of MTF2 were identified by HRM analysis in 147 newly presenting patients. Low TMED5 expression was weakly associated with short survival (median OS 29.9 months low expression vs 51.2 months, high expression, p=0.050).
However, no mutations were identified in 20 newly presenting patients.
1p12
Of 114 cases with mapping data, 1p12 was homozygously deleted in 2 cases and hemizygously deleted in a further 20 cases. In addition, uniparental disomy (UPD) was a mechanism of loss of heterozygosity in 4 cases. In an extended data set of 378 cases with FISH for 1p12, using a probe that was not specific for FAM46C, the rate of 1p12 deletion was 19%. When mapping of human myeloma cell lines only and 30 (8.1%) cases had deletion of both regions. The 38 patients with only del(1)(p12) were weakly associated with impaired survival (median OS 40.9 months vs 53.0 months, p=0.045), whilst there was a stronger association with short survival in patients with only del(1p)(32.3) (median OS 21.6 months vs 51.6 months, P<0.001). This suggests that when deletion alone is being considered, 1p32.3 has the largest prognostic impact.
DISCUSSION
In this analysis we identify genes and regions of 1p with prognostic impact and potential pathogenic relevance. 1p32.3 underwent homozygous deletion in 5.3% of cases, with the deletions affecting CDKN2C and also FAF1, although the mapping data of other data sets suggest that CDKN2C may be the key deleted gene (23) .
Deletions detected by FISH were associated with impaired survival in patients treated in the intensive arm of the Myeloma IX trial, but surprisingly the converse was true in patients treated non-intensively, with deletion being associated with a marginal improvement in OS. Both these associations were true in multivariate analyses including other genetic lesions, and we found no bias in confounding variables to explain this effect. We examined this paradox in more detail to assess whether this was related to patient therapy or patient age, and the association of deletion with impaired survival was only observed in patients receiving ASCT, suggesting that del(1)(p32.3) may specifically impair the response to this therapy. However, the low numbers of young patients not autografted in the analysis means that age cannot be completely discounted as a factor.
Whilst CDKN2C is likely to be the key deregulated gene in cases with homozygous deletion, it's involvement in the outcome of cases with hemizygous deletion was less certain, as in these cases CDKN2C was not under-expressed, and we have 
previously reported no evidence of allelic silencing through methylation or mutation (13) . Moreover, low expression was not associated with short survival but the converse was true, with high expression being linked to impaired survival. This is consistent with previously reported data showing that myeloma with high proliferation defined by a gene expression signature was associated with high CKDN2C expression (23). It is possible, then, that in patients with hemizygous deletion of 1p32.3, deletion of other genes may play a role in the clinical outcome. Whilst homozygous deletions were small and focal, mapping analysis showed that hemizygous deletions are often large and involve other regions, including 1p22.1 and 1p12.
1p22.1 was the most frequently deleted region in our mapping data set and in the extended analysis of all publically available mapping data sets. However, the two candidate genes that we had previously identified within this region (MTF2 and TMED5) did not have convincing evidence that down-regulation adversely affected survival. Moreover, we did not identify any mutations in these genes. Whilst it remains likely that this region has pathogenic relevance, a key de-regulated gene within this region has not been identified.
Homozygous deletions of 1p12 affecting only FAM46C were observed in two presenting myeloma patients and three HMCLs. In our initial gene mapping and expression data set we identified the potential importance of FAM46C, and this was confirmed in the report of the initial genome sequencing of 38 myeloma tumors which found FAM46C mutations in 5/38 patient samples and 4/17 HMCLs, and suggested a role for this functionally uncharacterized gene in regulation of translation by acting as an mRNA stability factor (11, 16) . We screened presenting myeloma tumors for variants of FAM46C by high resolution melt analysis, and found mutations in 5
Research. samples. The mutation rate was 3.4%, which is significant for presenting myeloma samples, but is lower than the 13% reported in the next-generation sequencing analysis. All our mutations were mis-sense mutations, as were 5/9 of the mutations reported previously (16) . FAM46C consists of two exons, with only part of exon 2 being translated, and is made up of 391 codons. It is notable that 35.7% (5/14) of mutations described in FAM46C in myeloma are in a small region between codon 173 and 186, suggesting that this may constitute a mutation hotspot ( Figure 5 ). As FAM46C shows occasional homozygous deletion in presenting myeloma cases, and has a reported mutation rate of between 3.4% and 13%, it likely represents a gene with pathogenic significance.
We examined the prognostic significance of abnormalities of this gene and region.
The association of deletion of 1p12 with adverse survival was confirmed by FISH in 379 patients, although the association was of borderline significance, and was not significant in multivariate analysis. Moreover, when cases with del(1)(p12) alone were compared to patients with del(1)(p32.3) alone, the association of del(1)(p32.3) with short survival was much stronger. A caveat of this extended analysis was that the FISH probe for 1p12 did not target FAM46C and may, therefore, have missed some FAM46C deleted cases. These analyses also did not consider FAM46C mutation events, which were frequent, and when we examined survival within patients with complete annotation of deletion and mutation of FAM46C, patients with any LOH or mutation of FAM46C were associated with impaired survival, although the numbers of patients involved in this analysis means that these results should be treated as preliminary. Taken together, these data suggest that when deletion alone is being considered, del(1)(p32.3) is the more prognostically important lesion.
However, if deletion and mutation events are considered together, FAM46C may still be prognostically important and future studies incorporating next generation sequencing data will illuminate this further. 
